Tridelta Drug Interactions

Ursodeoxycholic acid should not be administered concomitantly with charcoal, cholestyramine, colestipol or antacids containing aluminium hydroxide and/or smectite (aluminium oxide), because these preparations bind Ursodeoxycholic acid in the intestine and thereby inhibit its absorption and efficacy. Should the use of a preparation containing one of these substances be necessary, it must be taken at least 2 hours before or after Ursodeoxycholic acid.
Ursodeoxycholic acid can increase the absorption of Cyclosporine from the intestine. In patients receiving Cyclosporine treatment, blood concentrations of this substance should therefore be checked by the physician and the Cyclosporine dose adjusted if necessary.
In isolated cases, Ursodeoxycholic acid can reduce the absorption of Ciprofloxacin.
Ursodeoxycholic acid has been shown to reduce the plasma peak concentrations (Cmax) and the area under the curve (AUC) of the calcium antagonist Nitrendipine. An interaction with a reduction of the therapeutic effect of Dapsone was also reported.
These observations together with in vitro findings could indicate a potential for Ursodeoxycholic acid to induce cytochrome P450 3A enzymes. Controlled clinical trials have shown, however, that Ursodeoxycholic acid does not have a relevant inductive effect on cytochrome P450 3A enzymes.
Oral contraceptives, estrogenic hormones and blood cholesterol lowering agents such as Clofibrate may increase biliary lithiasis, which is a counter effect to Ursodeoxycholic acid used for dissolution of gallstones.